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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
death of upper and lower motor neurons, which results in muscle wasting and death from
respiratory failure typically within 2-5 years from diagnosis.
ALS is a multifactorial disease [1] where different cell types, i.e. astrocytes, microglia and
oligodendrocytes, contribute to the pathologic mechanism [2, 3]. For a long time ALS was
thought to be a pure motor neuron disease, however, thorough pathological investigations
and recent findings linking mutations in transactive response DNA-binding protein gene
(TARDBP) to familial and sporadic cases of ALS have relocated this disease within a spec‐
trum of neurological disorders, ranging from pure motor neuron disease to frontotemporal
dementia [4, 5].
Since 1993, when the first mutation in the Cu/Zn superoxide dismutase (SOD1) enzyme was
linked to familial forms of ALS, researchers have tried to unravel the mechanisms underly‐
ing this disease by interrogating in vivo and in vitro models overexpressing human SOD1.
Although these models have highly contributed to understanding the pathogenic mecha‐
nisms involved in motor neuron degeneration, they only account for less than 2% of all cas‐
es. Hence, the ALS field is still lacking effective therapies and a deep understanding of the
etiology of the sporadic disease.
For 15 years the SOD1 models have been the only available, until, in 2008, mutations in
TARDBP were found to be responsible for familial and sporadic forms of ALS [6, 7]. This led
to the discovery that mutations in a second RNA/DNA-binding protein called fused in sar‐
coma (FUS) or translocated in liposarcoma (TLS) were also cause of the disease [8, 9]. More
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recently, the field of ALS has seen a breakthrough with the association of GGGGCC-hexanu‐
cleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) to 35-40% of
familial cases and 5-7% of sporadic cases [10-12].
In the same years, from 2007 to present, in vitro technologies to model neurological disor‐
ders have also undergone an impressive development.
With the discovery that adult human fibroblasts could be reprogrammed to induced pluri‐
potent stem (iPS) cells with the use of selected transcription factors [13], the field of ALS saw
the opportunity to finally model not only the familial, but especially the sporadic disease in
vitro. In fact, in 2008, the first human iPS-derived motor neurons from patients were cul‐
tured in a petri dish [14]. Since then, several iPS lines have been produced from patients and
healthy individuals and they have been made commercially available (http://
www.coriell.org/stem-cells).
Moreover, in 2011, neural progenitors cells (NPCs) were isolated from post-mortem spinal
cord samples of ALS patients and successfully cultured and differentiated into motor neu‐
rons, astrocytes and oligodendrocytes in vitro [15]. This technology provided for the first
time the possibility to model all forms of ALS in vitro without inducing major epigenetic al‐
terations in the cells used.
In this chapter we will give an overview of how human tissues have been used so far, what
discoveries they have led to since 2007, and how the recent advances in technology com‐
bined with the recent genetic discoveries, have tremendously widened the horizon of ALS
research.
2. Latest genetic discoveries
Even though Jean-Martin Charcot initially described ALS in 1869, it took more than a centu‐
ry until the first disease-causing gene – the Cu/Zn superoxide dismutase (SOD1) - was iden‐
tified [16]. Mutations in this gene account for approximately 10-20% of the familial ALS
(FALS) cases (Anderson 2006) and about 1% of the sporadic (SALS). Up to now, mutations
in 21 different genes have been linked to ALS, although some of them present with atypical
disease characteristics [17]. FALS is usually inherited in an autosomal-dominant manner,
but in rarer cases, it appears also recessive or X-linked. Along with the rising number of
genes and mutations involved, the differentiation between sporadic and familial ALS be‐
comes increasingly difficult and depends on the definition applied. With the most stringent
classification, a patient is considered to suffer from the familial form if he/she has at least
one first- or second-degree relative affected by ALS [18]. However, other studies define
FALS when at least one relative is affected by motor neuron disease, i.e. ALS, primary later‐
al sclerosis (PLS) or progressive muscular atrophy (PMA) [19]. In addition, several indica‐
tions exist that mutations leading to ALS are also involved in the development of other
neurodegenerative diseases such as different types of dementia or Parkinsons disease. This
further broadens the range of possible familial linkage [19]. Missing family history data and
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the existence of mutations with incomplete penetrance, thus masking inherited genetic
forms of the disease as sporadic, further contribute to complicate the discrimination be‐
tween FALS and SALS.
In the last 20 years, most efforts were concentrated on studying the effect of SOD1 muta‐
tions, resulting in the generation of over 30 different animal models including Drosophila, C.
elegans, D. rerio, mice, rats and dogs [20]. In most cases, expression of human mutant SOD1 in
the animal models led to astrogliosis, inflammation and degeneration of motor neurons in a
similar manner as observed in patients.
The generated SOD1 animal models highly contributed to the understanding of SOD1 func‐
tions in the central nervous system (CNS) leading to the development of potential therapeu‐
tic strategies targeting these pathways. Unfortunately, most of the therapeutics that show an
effect in rodent models, fail in human clinical trials. Overall, SOD1 only accounts for about
2% of all ALS cases, therefore the question arose how applicable the findings from these
models really are for other familial cases and especially for the huge majority of sporadic
ALS cases.
In 2006, the transactive response DNA-binding protein (TDP-43) was identified as a major
component of intraneuronal inclusions, a form of protein aggregates representing a hall‐
mark of SALS and non-SOD1-FALS cases [21]. Soon after, researchers found ALS causing
mutations in this gene [6, 7]. One year later, mutations in a second RNA/DNA-binding pro‐
tein called fused in sarcoma (FUS) or translocated in liposarcoma (TLS) were published [8,
9]. While TDP-43 mutations account for 4% of FALS, FUS mutations are less frequent and
account for approximately 1-2% [22]. The discovery of the involvement of these two genes
can be considered a milestone in ALS research, not necessarily because of the mutation fre‐
quency, but rather because of the wide presence of these proteins in the aggregates charac‐
terizing tissues from sporadic ALS cases. Mutations in TDP-43 and FUS can also be found in
some forms of frontotemporal dementia (FTD), while aggregates of the non-mutated protein
seem to be an even more common feature for neurodegenerative diseases including Hun‐
tington’s, Alzheimer’s and Parkinson’s [23]. As both proteins are involved in RNA metabo‐
lism, a common disease mechanism underlying sporadic and familial forms of ALS might
exist. This link rises hope that a common therapeutic strategy could be developed benefit‐
ting a broad patient population.
The TARDBP gene encoding TDP-43 lies on chromosome 1p36.2. The TDP-43 protein con‐
sists of 414 amino acids and is highly conserved among species [7]. The expression pattern is
almost ubiquitous with high levels during development. Loss of TDP-43 is detrimental in
rodents as knockouts in mice are lethal in both cases, either when performed during embry‐
onic stages, or also as conditional knockouts in the adult mouse [24-26]. As mentioned
above, the protein is involved in RNA metabolism, but therein, various functions including
regulation of alternative splicing, transcription, miRNA levels, RNA stabilization, as well as
formation of stress and RNA granules have been described. TDP-43 seems to preferentially
bind RNAs with unusually long introns and/or such that are involved in neuronal function
like synaptic activity and neuronal development. Some of these RNAs encode proteins
which have previously been shown to be involved in neurodegenerative diseases [27]. Al‐
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though TDP-43 depletion affects the expression and splicing of many different RNAs in the
CNS, the vast majority of the more than 40 ALS causing mutations identified so far, lie with‐
in the C-terminal domain encoding a glycine rich stretch that is important for protein-pro‐
tein interaction. While in healthy individuals TDP-43 is mainly localized in the nucleus, it
gets mislocalized and trapped in cytoplasmic aggregates in ALS patients, leading to reduced
levels in the nucleus [22]. The trapped TDP-43 seems to be heavily modified displaying
ubiquitination, phosphorylation and cleavage and in some cases, misfolding. The exact
meaning of TDP-43 mislocalization in ALS and other neurodegenerative diseases remains to
be elucidated, as so far, it is unclear whether the inclusions actively participate in the disease
development and progression or rather represent a mere indicator of other dysregulated cel‐
lular mechanisms. The observed changes in RNA regulation could arise from both, the mis‐
localization itself, leading to a reduced abundance in the nucleus, or function altering
mutations or modifications of the protein. In addition, it was reported that certain mutations
increase the stability of the protein and therefore its overall abundance in the cell [28], which
might lead to the visible accumulations and alterations in RNA metabolism.
Until now, a plethora of different animal models including Drosophila, mouse and rats has
been generated. Unfortunately at present, TDP-43 models have originated controversial re‐
sults. In fact, overexpressing wild type TDP-43 in the CNS appears to be toxic by itself,
while the effects of the mutant protein vary broadly ranging from no symptoms to severe
neurodegeneration in different regions of the mouse brain [20]. Mostly, it is unclear whether
the toxicity is due to the mutation or the simple presence of the transgene.
The gene  encoding FUS lies  on chromosome 16  in  a  region that  was  already linked to
familial ALS before the first mutations were identified. After the discovery of TDP-43 mu‐
tations, the focus on genes encoding RNA/DNA-binding proteins increased leading to the
fast discovery of mutations in FALS patients by two independent groups [8, 9]. Similar to
TDP-43, more than 40 different FUS mutations have been identified in FALS patients or
patients  suffering  from  FTD.  The  FUS  protein  consists  of  526  amino  acids  and  like
TDP-43,  it  is  widely  expressed  amongst  different  tissues.  Knockout  of  FUS in  different
mouse strains led to differing results, indicating that the genetic background of the used
mouse strain plays an important role as disease modifier. In the inbred strains (C57BL/6
and 129), the knockout causes death at birth, whereas outbred strains survive until adult‐
hood.  In  all  cases,  FUS depletion  seems not  to  induce  classical  neurodegeneration  as  a
primary effect.  Interestingly,  unlike TDP-43,  the ALS related mutations in the FUS gene
do not cluster in the glycine-rich region of the protein, but rather at the very end of the
highly  conserved C-terminus of  the  protein  that  contains  the  nuclear  localization signal
[22].  FUS is  also  mainly  localized in  the  nucleus  of  cells  in  healthy individuals,  but  its
mislocalization and aggregation in cytoplasmic granules in ALS patients leads to a less se‐
vere reduction in the nucleus than TDP-43 [22]. Up to now, only few binding partners of
FUS (RNA or proteins) are known, making it  further challenging to speculate about the
function of the protein, which remains mostly unknown. In general, FUS is thought to be
involved  in  regulation  of  gene  expression,  transcription,  RNA  splicing,  RNA  transport,
translation, miRNA processing as well as DNA damage repair [29]. Interestingly, TDP-43
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and FUS might directly interact with each other as they were detected in the same com‐
plex in cultured cells [28, 30]. Even though further data from patients and animal models
are  needed to  confirm this  finding,  it  is  an interesting observation,  as  TDP-43 does  not
seem to be  mislocalized in  ALS cases  that  have accumulation of  FUS containing aggre‐
gates in the cytoplasm [28].
Following TDP-43 and FUS, the thorough analysis of the cytoplasmic aggregates found in
ALS patients led to the identification of additional common components such as optineurin
and ubiquilin-2. Several of these proteins were afterwards identified to be mutated in a
smaller portion of ALS patients as well [31].
In 2011, the identification of a new ALS gene harboring a different type of mutation was
achieved.  The  association  of  the  chromosomal  locus  9p21.2  with  ALS and FTD had al‐
ready been described in 2006 [32]. The improvement of sequencing techniques and contin‐
uous  research  finally  led  to  the  identification  of  the  disease  causing  gene:  C9ORF72.
While the function of this widely expressed protein is unknown, the type of mutation dif‐
fers from other ALS related genes.  It  consists of a massive GGGGCC-hexanucleotide re‐
peat expansion in intron 1 between two non-coding exons.  Whereas healthy individuals
carry up to about 23 repeats, affected patients have at least 30, but in some cases, many
hundred copies of it [11, 12].
The first reports about the mutation in this gene came from two independent studies analyz‐
ing relatively small cohorts respectively of sporadic and familial ALS cases in Finland and
Europe and ALS/FTD cases in the USA. Both studies started off with re-sequencing of the
9p21.2 locus from well defined families, in which the linkage of the disease to this chromo‐
some 9 location had been previously demonstrated [11, 12]. After the detection of the repeat,
the analyses were expanded to larger cohorts.
The most striking discovery of these studies is the high frequency of mutations in this gene
in the analysed cohorts. Between 9 and 20% of American patients suffering from familial
FTD and up to 38% of familial ALS cases from different European countries resulted posi‐
tive for the new mutation. For the sporadic cases, the percentage lies around 7% for the
American FTD patient population and 21% of sporadic ALS patients in the genetically ho‐
mogenous Finnish population. With these initially published percentages, C9ORF72 muta‐
tions appeared to be the so far most frequent known cause of ALS and FTD. However, the
cohorts were recruited through only few institutions and were rather small. Recently, a
cross-sectional study including more patients from various different countries and with dif‐
fering genetic background has been published. In this study, a total of 588 familial ALS cases
and 403 familial FTD cases were screened for the mutation. For FALS, 37.6% of patients
were identified to carry the pathological repeat, for FTD the percentage was 25.1% [33]. Al‐
though further studies are needed to confirm these findings, they are truly exciting, consid‐
ering the fact that together with SOD1, which accounts for approximately 10-20% of FALS,
almost 50% of the familial disease cases can now be explained by mutations in one of these
two genes.
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The observation that C9ORF72 mutations not only cause ALS, but also FTD and clinically
mixed syndromes such as ALS-FTD, is in line with the clinical spectrum caused by TDP-43
and FUS mutations as well as wild type aggregations in both diseases. This further strength‐
ens the indications that these two clinically distinct syndromes share a common pathogenic
link [19, 34].
Interestingly, the pathological features of C9ORF72 related ALS seem very unusual and dis‐
tinct up to the point that the mutation itself can actually be predicted from the observed
pathology [35]. While the spinal cord shows the typical neuronal loss and TDP-43 positive
cytoplasmic inclusions, other regions of the brain seem to accumulate aggregates that are
widely devoid of TDP-43 and contain p62.
The mechanism through which this expansion repeat conveys toxicity to neurons still has to
be elucidated. Two major hypotheses can be distinguished: 1) The expansion repeat alters or
abolishes expression of all or certain C9ORF72 protein isoforms leading to reduced protein
levels and a loss of functionality, 2) the expanded repeat itself conveys toxicity by sequestra‐
tion of other RNA binding proteins and aggregate formation inside the nucleus, thus inhib‐
iting proper functionality of the bound proteins. To date, it is not known which hypothesis
applies in the case of C9ORF72 expansions, but the experience from various other toxic ex‐
pansion repeat diseases like Huntington’s disease are favoring the second. While Renton et.
al demonstrate the presence of aggregates in the nucleus of fibroblasts from affected pa‐
tients, the results from the second study by DeJesus et al are less clear concerning accumula‐
tion of RNA granules. The latter study also lies more emphasis on a change in the
expression levels of different C9ORF72 mRNA isoforms, which would support the first hy‐
pothesis rather than the second. Currently, the tools for a detailed analysis of protein expres‐
sion and function are still lacking, but considering the importance of the mutation, huge
efforts are put into the development of better antibodies, probes and assays.
Overall, the finding that mutations in TDP43, FUS and C9ORF72 might cause ALS by alter‐
ing the normal interaction of these proteins with RNA or might cause a toxic gain of func‐
tion leading to unexpected protein-RNA interaction opens new avenues for ALS research.
These recent genetic discoveries have shifted the attention to cellular processes, i.e. RNA
metabolism, transport and processing, that were not under investigation in the SOD1 mod‐
els. These pathways might represent a common mechanism for different forms of ALS, as
well as creating a link between ALS and a wider spectrum of neurodegenerative conditions.
3. The role of wild type SOD1 in ALS
In 1993 for the first time mutations in SOD1 were identified as cause of familial ALS and
were found to be responsible for about 20% of familial cases [16]. Since that discovery nearly
twenty years ago, more than 160 mutations in SOD1 have been identified (http://
alsod.iop.kcl.ac.uk/) and cellular and animal models of the disease carrying different forms
of mutant SOD1 have been generated [36, 37]. Experiments using animal models revealed
that the toxicity of mutant SOD1 is not related to a loss of function of the enzyme [38], but
Current Advances in Amyotrophic Lateral Sclerosis164
rather a gain of toxic function. In the past twenty years different forms of mutant SOD1 have
been characterized for their biochemical properties, however no common characteristics be‐
tween mutations have been found. In fact, different mutations seem to cause different
changes in enzymatic function or no change at all [39-41], leading to the conclusion that
SOD1 dismutase activity is not responsible for protein toxicity. Although the nature of the
toxic function gained by mutant SOD1 is still obscure, there is clear evidence that the mutant
enzyme undergoes conformational changes leading to its misfolding and subsequent aggre‐
gation [41, 42]. SOD1 aggregates are, in fact, one of the histological hallmarks of SOD1-relat‐
ed FALS, as well as sporadic cases carrying SOD1 mutations.
Although SOD1 mutations are responsible for less than 2% of ALS cases and this disease is
mainly of sporadic origin, sporadic and familial cases are clinically undistinguishable. More‐
over, with the exception of patients carrying C9ORF72 mutation, which seem to define a
specific clinical subgroup [35], other genetic mutations do not determine different clinical
characteristics. This observation has led to the conclusion that familial and sporadic ALS
must share common pathogenic mechanisms [1]. Consequently, in recent years, efforts have
been made in understanding whether the genes causing familial ALS can be responsible or
can be involved in the pathophysiology of sporadic cases. Recently, strong evidence has
been gathered suggesting that SOD1 might play a crucial role also in SALS.
Wild-type human SOD1 is a 32KDa homodimer known to be one of the most stable proteins
with a melting temperature around 90°C. However, its stability is highly dependent upon
post-translational processes including binding of copper and zinc ions and the formation of
an intramolecular disulfide bond. Impairment or retardation of these post-translational
processes can disrupt SOD1 stability, causing the formation of misfolded structures and ag‐
gregates. Indeed, in 2007, it was shown that oxidised wild-type SOD1 could acquire in vitro
aberrant properties leading to association with poly-ubiquitin, Hsp70 and chromogranin B,
similarly to the mutant enzyme [43]. The same year, another group used covalent chemical
modification to show that spinal cord samples from both familial and sporadic ALS cases
displayed a form of SOD1 that was absent in non-neurological controls as well as in spinal
cord samples from patients affected by other neurodegenerative disorders [44]. Recently,
Guareschi et al [45] managed to immunoprecipitate SOD1 from sporadic and familial ALS
patients’ lymphoblasts and then analysed the presence of oxidized carbonyl groups. A form
of over-oxidized wild-type SOD1 was indeed found in a subset of SALS patients. This post-
translationally modified form of the wild-type enzyme recapitulates some of the toxic prop‐
erties attributed to mutant SOD1, i.e. the ability to cause mitochondrial damage through
interaction with Bcl-2 [45]. Altogether, these findings supported the hypothesis that SOD1
could be a link between familial and sporadic ALS.
On another front, the use of the SOD1 mouse model also provided important clues as to
whether normal SOD1 can play a role in the disease. Surprisingly, overexpression of wild-
type human SOD1 accelerated disease onset in several transgenic mouse models of ALS [46,
47], supporting the involvement of wild type SOD1 in the disease mechanism. However,
these results have to be interpreted with caution, as they might derive by the toxicity of
transgene accumulation rather than a specific SOD1-related mechanism.
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In order to determine whether in vivo wild-type SOD1 can undergo misfolding and can be
detected without altering the original sample, recent studies have focused on the production
and investigation of new antibodies able to distinguish mutant/misfolded/monomeric SOD1
as opposed to its wild-type form. Although some of these antibodies have been tested only
on limited samples and their ability to discriminate between aberrant conformations of
SOD1 is debatable, their use has led to potentially interesting findings. One of the first anti‐
bodies produced to detect abnormalities in SOD1 post-translational processing was the
SOD1-exposed dimer interface (SEDI). This antibody was prepared with the peptide at the
dimer interface of SOD1. When SOD1 is folded as a homodimer in its active state, this site is
inaccessible, while it is exposed upon monomerization [48]. This antibody successfully
stained inclusions in motor neurons from SALS samples, however it did not detect positive
inclusions in SALS spinal cords where no SOD1 mutations were detected [49]. Similarly, an
antibody developed against the region Leu42-His48, which specifically recognizes SOD1 in
which the beta barrel is unfolded, failed to detect misfolded SOD1 in SALS spinal cord sam‐
ples, but succeeded in recognizing aggregates in the FALS samples [50]. Despite these re‐
sults, it could not be concluded that wild-type SOD1 does not contribute to the pathogenic
mechanisms occurring in SALS. Indeed, Forsberg et al. have produced a series of polyclonal
antibodies against several SOD1 peptides that react with the denaturated enzyme, but not
with the wild-type form. Using these antibodies, small inclusions were detected in the motor
neurons of SALS patients [51] as well as in the nuclei of astrocytes, microglia and oligoden‐
drocytes [52]. These studies supported the hypothesis that wild-type SOD1, although not in‐
volved in the formation of Lewy body-like inclusions in SALS, is likely to undergo
conformational changes, thus contributing to the pathologic mechanism.
Another antibody that has been used to detect misfolded SOD1 is C4F6. This peptide was
raised against metal depleted (apo) SOD1 with G93A mutation [53]. Although this antibody
was raised against a specific mutant form of SOD1, it successfully recognised skein-like in‐
clusions in FALS spinal cord samples, as well as inclusions in SALS [54].
Recently, a monoclonal antibody, called 3H1, was used to detect misfolded SOD1 in a subset
of SALS cases displaying TDP-43/FUS-positive inclusions. This antibody recognizes a pep‐
tide corresponding to a structurally disrupted SOD1 electrostatic loop, detectable only when
the protein is misfolded. Spinal cord immunocytochemistry showed that, in some SALS
samples, TDP-43/FUS-positive inclusions were also positive for 3H1 antibody, suggesting
that the pathologic mechanisms involved in ALS might trigger SOD1 misfolding, thus trig‐
gering toxic pathways common to both sporadic and familial ALS [55].
Besides the efforts to generate antibodies able to detect misfolded SOD1, no consensus has
been reached on which antibodies, if any, can reliably and consistently detect the different
forms of misfolded SOD1. Other studies have, therefore, used a different approach, trying to
understand whether normal SOD1 shares common characteristics with the mutant form of
the enzyme. Recently, a novel rare mutation in SOD1 (L117V) was identified in two Syrian
ALS families [39]. Unusually, the disease showed uncommon low penetrance and slow pro‐
gression. Biochemical analysis of L117V SOD1 showed that its properties were indistin‐
guishable from the wild-type form and yet causing the disease. This study highlights that
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normal SOD1 is in the range of protein stability that can cause disease and suggests that mu‐
tant forms of SOD1 with high stability might be related to low penetrance and be therefore
categorized as sporadic forms of ALS. The authors suggest that, similarly, other complex ge‐
netic, environmental and lifestyle factors can influence the stability of normal SOD1 causing
its misfolding in SALS cases. However, this does not exclude that the toxicity related to
L117V mutation could derive by the interaction with other proteins and not by its stability.
The importance of finding common pathways or players between sporadic and familial ALS
is crucial for therapeutic approaches. One recent study explored this possibility [15]. The au‐
thors assessed the toxicity of astrocytes derived from neural progenitors isolated from the
spinal cord of sporadic and familial ALS patients. This study showed for the first time that
astrocytes from sporadic cases of disease are as toxic to motor neurons as astrocytes carrying
mutations in SOD1. As expected, the shRNA mediated reduction of mutated SOD1 led to a
complete rescue of motor neurons in this co-culture system. Of particular interest however,
was the finding that even the knock down of wild type SOD1 in astrocytes from sporadic
patients markedly attenuated toxicity towards motor neurons.
The data summarized in this section provide strong evidence for a pathologic role of wild-
type SOD1 in sporadic disease. This hypothesis opens new frontiers for future therapeutic
approaches in the treatment of ALS.
4. Human samples to study ALS
In ALS the cells mainly affected by the disease, the motor neurons and the glia, are located
in the motor cortex and the spinal cord, which are accessible only post-mortem. The scarce
availability of CNS samples, along with post-mortem delay and different preservation tech‐
niques that can affect the quality of the tissue and limit its use, are great challenges when
studying this disease. Moreover, post-mortem material is only representative of the end
stage of disease and, although used in microarray studies to unravel the mechanisms of neu‐
rodegeneration, it is unlikely to help identify early biomarkers. For these reasons, peripheral
tissues, i.e. blood, fibroblasts and cerebrospinal fluid (CSF) have been preferentially used in
high-throughput screening assays for biomarkers identification as well as gene expression
profiling.
4.1. Gene expression profiling
Multiple research groups have used post-mortem samples to identify the pathways in‐
volved in the neurodegenerative process of ALS. The studies utilizing complex tissues, rep‐
resentative of a mixed cell population, i.e. motor cortex [56] or spinal cord [57], have mainly
recorded gene expression changes indicating the presence of an aggressive inflammatory re‐
action and active astrogliosis. These processes are prevalent in the spinal cord of ALS pa‐
tients and have masked the transcriptional changes occurring in motor neurons. However,
the motor cortex seems to be affected to a lesser extent by astrogliosis and this enabled Le‐
derer and colleagues to identify important changes in transcripts involved in the cytoskele‐
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tal, mitochondrial and proteasomal functions, as well as ion homeostasis and glycolysis [56],
in agreement with other lines of research in ALS [1].
In order to determine those genes differentially expressed in the cell type most affected in
ALS, i.e. spinal motor neurons, laser capture microdissection (LCM) has been used to isolate
single cells from human post mortem spinal cord samples.
Gene expression profiling of motor neurons has been performed on sporadic ALS cases [58],
as well as ALS cases carrying mutations in the SOD1 and chromatin modifying protein 2B
(CHMP2B) genes [59, 60]. The three studies highlighted the activation of different pathogen‐
ic pathways. The motor neurons isolated from sporadic cases showed decreased expression
of genes associated with the cytoskeleton and transcription, whilst cell death-associated
transcripts were increased. Moreover, genes involved in cell cycle activation and progres‐
sion were found to be upregulated, supporting the theory that inappropriate activation of
the cell cycle in these post-mitotic cells can lead to cell death [58].
In contrast, microarray analysis of motor neurons isolated from SOD1-related ALS cases
highlighted the activation of a cell survival pathway in the motor neurons that were spared
by the disease. The study, in fact, revealed differential expression of genes involved in the
protein kinase B/phosphatidylinositol-3 kinase (AKT/PI3K) pathway, along with decrease in
phophastase and tensin homologue (PTEN) gene, a negative regulator of AKT [60]. The au‐
thors also showed that inhibition of PTEN led to increased activation of the AKT/PI3K path‐
way, with beneficial effects on primary motor neuron survival. Thus, activation of the AKT/
PI3K pathway is a potential candidate for future therapeutic strategies.
Finally, the transcriptional profiles from motor neurons isolated from the CHMP2B-related
ALS cases showed dysregulation of genes involved in p38 MAPK signalling pathway, re‐
duced autophagy and repression of translation [59]. The significant impairment of the au‐
tophagy pathway reflects the function of CHMP2B, the gene mutated in these patient
samples.
In spite of the differences between the pathways described above, dysregulation of calcium
handling and cell cycle, as well as transcription, cytoskeleton assembly and metabolism,
were common between the different genetic subtypes and SALS. Taking into account that
these results derive from end-stage tissues, they support the evidence that etiologically di‐
verse forms of ALS converge into common mechanisms involved in motor neuron death.
4.1.1. Results from use of human peripheral tissue
Gene expression profiling has also been conducted on blood cells from ALS patients in order
to identify biomarkers and/or achieve a better classification of disease subtypes through the
identification of common transcriptional patterns [61-63]. In the study conducted by Saris
and colleagues, microarray analysis of SALS and control whole blood samples was followed
by hierarchical clustering of all differentially expressed transcripts [61]. This approach suc‐
cessfully identified different clusters that were able to differentiate between ALS and control
samples. Interestingly, this study showed that peripheral blood can be used to investigate
the pathways activated during disease, as the blood from ALS patients reveals decrease in
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transcripts involved in RNA processing as well as upregulation of inflammatory genes. This
suggests that the mechanisms affecting motor neurons, also strike other cell type. However,
because of their post-mitotic characteristics and their unique function, motor neurons are the
most susceptible.
A more recent study performed gene expression profiling on peripheral blood mononuclear
cells (PBMCs) from patients with SALS [62]. The results show upregulation of LPS/TLR4-
signaling associated genes in response to elevated LPS plasma levels. A similar transcription
pattern was obtained by culturing PBMCs from normal controls with LPS for a short time in
vitro.
Similarly, Mougeot et al. found that peripheral blood lymphocytes (PBLs) display dysregu‐
lation of the ubiquitin/proteasome system (UPS) [63]. In particular, microarray analysis re‐
vealed upregulation of the ubiquitin-protein ligase E3-alpha-2 (UBR2) expression. UBR2 is
known to act in synergy with UBR1 in a quality control mechanism for degradation of un‐
folded proteins. UBR2 upregulation correlated inversely with time since onset of disease
and directly with the ALS functional rating scale (ALSFRS-R), suggesting that UBR2 is in‐
creased early in the disease course and decreases as disease progresses. The authors con‐
firmed with in vitro experiments that cultured PBMCs from ALS patients accumulated more
ubiquitinated proteins than PBMCs from healthy controls in a serum-dependent manner, as
expected from the transcription data.
Very recently, human samples have been used to interrogate micro RNA (miRNA) expres‐
sion [64, 65]. Two studies successfully identified dysregulation of miRNAs in peripheral leu‐
kocytes [64] and monocytes [65] from SALS samples compared to controls. These miRNA
are involved in pathways relevant to the CNS and, in particular, Butovsky et al. identified
changes relevant for the inflammatory response, similarly to the expression pattern dis‐
played by monocytes isolated from multiple sclerosis (MS) patients. These results suggest
that miRNAs profiles found in the peripheral blood cells can be relevant to understand the
pathogenesis of ALS and/or used as biomarkers of the disease.
4.2. Biomarkers in ALS
ALS is fatal rapidly progressive neurodegenerative disorder, characterized by the activation
of an intricate network of pathways and still lacking an effective treatment beside Riluzole
[1]. The diagnosis of ALS is still mainly based on clinical assessment of progression of symp‐
toms, which results in a delay of about a year from symptom onset to diagnosis. Although
the clinical course of disease can considerably vary from case to case, in the majority of cases
death occurs within 2-5 years [66].
In this scenario, significant effort has been spent trying to identify molecules that could help
classify different forms of ALS and lead to early diagnosis, as well as monitor disease pro‐
gression.
The tissues mainly utilized for biomarker screening in the past five years have been periph‐
eral blood mononuclear cells (PBMCs) and cerebrospinal fluid (CSF). PBMCs have already
been shown to display some of the traits of the disease, such as increase in inflammatory
The Use of Human Samples to Study Familial and Sporadic Amyotrophic Lateral Sclerosis: New Frontiers…
http://dx.doi.org/10.5772/56487
169
genes [65] and downregulation of Bcl-2 [67] and might, therefore, be used to investigate the
disease during its progression as well as provide unique biomarkers.
Recently, Nardo et al. performed proteomic analysis of PBMCs isolated from 60 sporadic
ALS patients and 30 healthy controls [68]. The authors identified and validated in a second
cohort 14 protein biomarkers, that could discriminate between ALS patients and controls re‐
gardless of age and gender. Remarkably, of these 14 biomarkers, 5 were able to discriminate
between ALS patients and individuals with other neuropathies and 3, among which TDP43,
were markers of disease severity. Notably, these results are consistent with a CSF biomarker
study reporting that TDP43 levels were increased in ALS patients [69]. The value of this re‐
sult goes beyond the finding of a disease biomarker, as it supports the even more interesting
hypothesis that TDP43 could be a common player in early disease in familial as well as
sporadic ALS cases. This would confirm what is already suggested by the presence of
TDP-43 positive aggregates in SALS biopsy samples.
Although there is still no consensus on valid biomarkers for ALS [70], proteome analysis has
recently led to the identification of fetuin-A and transthyretin (TTR) as candidates to distin‐
guish ALS patients with rapid versus slow disease progression. The upregulation of TTR
and fetuin-A, involved in immune regulatory functions, could be associated with the inflam‐
matory state of the CNS. At present, these markers were tested in two independent cohorts
of 18 and 20 patients with a follow up of 2 years [71] and TTR had already been identified as
a potential biomarker for ALS compared to controls in a previous study [72]. Although fur‐
ther validation is needed, these results are encouraging and would provide an invaluable
tool to discriminate between patients with different disease progression rates. This would
help clinician determine the timing for clinical intervention such as gastrostomy and non-
invasive ventilation [73].
5. Stem cell technology for ALS research
Stem cells are defined as a population of cells that maintains the ability to self-renew and
differentiate into several cell types of the adult body. In mammals, several tissues such as
muscle, brain and bone marrow, harbor subtypes of stem cells that can give rise to a rela‐
tively small variety of different cell types. These adult stem cells are committed to certain
cell lineages and do not produce cells from other tissue types under normal conditions. Un‐
like adult stem cells, embryonic stem cells that can be isolated from the inner cell mass of
early stage embryos are pluripotent and can, therefore, still differentiate into virtually any
cell type of the human body. While the collection of embryonic stem cells from mice is a
widely accepted approach used for disease modeling, the use of human embryonic stem
cells is controversial and rises severe ethical concerns. With the discovery that adult human
fibroblasts can be reprogrammed to an embryonic stem cell like state, new hope arose for
stem cell based approaches in human research. Induced pluripotent stem cells (iPS) are usu‐
ally generated by the introduction of 2-5 defined pluripotency transcription factors into fi‐
broblasts or other readily available differentiated cell types. These transcription factors
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drastically alter gene expression in the target cells until some of them eventually become
pluripotent and can then be isolated and amplified. Initially, the transcription factors were
introduced by retroviral or lentiviral constructs leading to the integration of the transgene
into the target genome. As the random integration of additional genes can disrupt/alter the
expression of endogenous genes, more recent approaches rely on less invasive techniques
such as transposons or RNA transfection [74]
The use of stem cell technologies in ALS research started in 2007 when mouse embryonic
stem cells from the most prominent SOD1 model carrying the G93A mutation were estab‐
lished [75]. When differentiated into motor neurons, mild phenotypic differences between
motor neurons expressing human wild type SOD1 or the G93A mutation could be observed.
After several weeks in culture, SOD1 containing inclusions as well as the overall level of
ubiquitinated proteins were more frequent in the motor neurons expressing the mutant hu‐
man protein. In 2009, a human embryonic stem cell line was used to generate motor neurons
that were then transfected with different SOD1 mutation containing constructs [76]. The re‐
searchers observed a reduction in neurite length and in line with the study of the mouse
G93A embryonic stem cell derived motor neurons, reduced survival. However, in the hu‐
man study, it is unclear whether the observed phenotype arises from the mutations or the
increase of SOD1 abundance itself, as a control overexpressing wild type SOD1, was not
generated.
Since the discovery of the iPS technology, huge efforts were put in the generation of patient
specific iPS lines. Up to now, several hundred lines with various mutations have been gener‐
ated and some are now becoming commercially available thereby getting accessible to a
broad scientific community.
In 2008, Dimos et al reported the successful generation of motor neurons and glial cells from
an ALS patient derived iPS line carrying a SOD1 mutation causing a mild disease phenotype
[14]. Surprisingly, unlike the previous studies with mouse and human embryonic stem cells,
no disease related phenotype was reported from these cells until now. This potential lack of
phenotype could in part be explained by the patient’s late onset and mild disease form. An‐
other report from 2011, where motor neurons were generated from a patient harboring a
VAPB mutation, did also not mention any phenotype despite reduced levels of VAPB. As
the levels of this protein were already reduced in the fibroblasts used for the reprogram‐
ming, the lower levels in the resulting motor neurons could either be due to mutation in‐
duced expression or translational changes or could also be explained by an incomplete
reprogramming of this genomic locus in the generated iPS lines [77]. Recently, the first re‐
port of an iPS line harboring a TDP-43 mutation was published [78]. The motor neurons
generated from this line showed elevated TDP-43 levels, but no change in localization or
signs of aggregate formation. In addition, motor neurons from both, control and TDP-43
mutant were phenotypically and functionally similar despite an elevated sensitivity to PI3K
signaling inhibition and elevated cell death. These data suggest that the toxicity of this
TDP-43 mutation might arise from its increased stability leading to a higher overall protein
amount in the cell.
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Despite the growing number of iPS lines from ALS patients available, no further reports of
disease relevant phenotypes or major discoveries of disease mechanisms from the use of
these cells were reported so far. In addition, observations from other neurological disorders
show a similar trend: cells differentiated from embryonic stem cells or induced pluripotent
stem cells often reflect only certain aspects of the disease and sometimes it takes several
weeks before such differences can be recorded and/or the observed symptoms are very mild
[79, 80]. The problems to reproduce patient phenotypes have ameliorated the initial excite‐
ment about this new method to model neurological diseases. More recently, it became clear
that even cells differentiated from individual embryonic stem cell clones or iPS clones from
the same patient can show substantial phenotypic differences, a phenomenon called clonal
variation [81]. Similar observations were made in a study using iPS lines of ALS patients
carrying TDP-43 mutations. After differentiation of individual iPS clones from the same pa‐
tient into motor neurons, the levels of TDP-43 expression as well as aggregate formation and
oxidative stress induced cell death showed substantial variation [82]. Considering the con‐
fusing reports, it has to be assumed that the reprogramming as well as the following differ‐
entiation mechanisms are not yet fully under control and more mechanistic research and
standardization of the protocols will hopefully soon lead to more pronounced and reprodu‐
cible results. Initial steps to improve reproducibility and differentiation are already under
way. The main focus lies on the standardization of the initial characterization of the iPS
clones prior to use as well as the improvement of differentiation protocols by addition of
various small molecules and growth factors [83, 84].
While these approaches emerge, sporadic and familial forms of ALS can be modeled with
cells isolated from human post mortem spinal cord or brain samples. A recent report dem‐
onstrated that post-mortem isolated neuronal progenitor cells from patients with sporadic
or familial ALS, can be differentiated into astrocyte-like cells in vitro. Astrocytes from pa‐
tients, but not from healthy controls conveyed toxicity to wild type mouse motor neurons in
a co-culture [15]. This system provides a promising tool for testing of potential therapeutic
approaches.
5.1. The promises and limitations of stem cells for therapeutic approaches
The disease modeling described in the upper section is in particular important for the huge
proportion of ALS cases, where no causing mutation is known. Until the discovery of the
iPS technology, this lack of knowledge made it impossible to model such cases in vitro in a
cell based assay or with animal models, unless post-mortem cells could be collected. Now
we can use skin fibroblasts or other readily available cell types from affected patients during
different time points of disease progression prior to end stage. From these fibroblasts, vari‐
ous cell types that are known to play a crucial role in ALS can be generated and their behav‐
ior and interplay in a cell culture dish can be studied in-depth.
Despite emerging into an invaluable tool to study disease mechanisms, stem cells also hold
a huge potential for the development of therapeutic approaches for ALS and many other
neurodegenerative diseases. On the one hand, the generated cells can now be used in drug
screenings to identify new target mechanisms or to assess potential new therapeutics. On
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the other hand, the stem cells can be used for cell replacement approaches. For patients with
known mutations, the cells can be genetically modified or corrected prior to reprogramming
and differentiation. Such individualized strategies would allow the use of the patient’s own
cells for transplantation, thereby reducing the risk of graft rejection.
In ALS, a major future goal would be to produce and replace dying motor neurons. A proof
of principle that motor neuron transplantation might become possible came from the obser‐
vation that mouse embryonic stem cell derived motor neurons transplanted into the lumbar
part of paralysed adult rats can actually survive and form functional neuromuscular junc‐
tions leading to phenotypical improvements [85]. However, in human ALS patients, the re‐
placement of motor neurons might be more complicated due to the size differences, amount
of cells needed and distance that the axon would have to grow out. In addition, it becomes
more and more evident that ALS is a non-cell autonomous disease in which astrocytes, mi‐
croglia and oligodendrocytes play a crucial role in modulating disease onset and progres‐
sion [3, 15, 86]. In this context, a strategy approaching several cell types at a time might be
more successful than bringing in healthy motor neurons alone into a heavily diseased envi‐
ronment. A promising candidate that can generate various cell types in the CNS and at the
same time positively stimulate the neuronal environment by producing neuroprotective fac‐
tors, are neuronal progenitor cells (also called neuronal stem cells). Several reports indicate
that transplanted neuronal progenitor cells are able to differentiate into different cell types
in vivo [87, 88]. Further, injection of NPCs has been shown to ameliorate disease progression
in ALS rodent models even if most of the cells do not migrate or differentiate into other cell
types in various neurodegenerative diseases [89]. However, it is not known how these cells
would behave and survive when transplanted into a diseased environment.
One of the largest limitations for cell replacement strategies to date is the lack of efficiency
as well as specificity during the amplification and differentiation step. The differentiation of
ES or iPS cells into various different neurons or neuronal progenitor cells is guided by the
application of different growth factors and small molecules. However, this process usually
generates a mixed population containing many different cell types. The cell type of interest
often represents only 30% or even less of the total population. Therefore, it might be difficult
to generate enough cells for therapeutic applications.
When using ES or iPS lines to generate the cell type of interest, a further drawback is that a
small portion of cells remains undifferentiated and immature, thereby representing a major
risk factor for transplantation [90]. When neuronal progenitor cells derived from mouse iPS
cells were injected into adult mouse brains, they formed tumors in up to 60% of the injected
animals [88]. The use or more restricted cell types such as NPCs on the opposite, appears to
be safer.
Finally, the generation and maintenance of a stable iPS lines from human adult cells is ex‐
pensive and very time consuming [74]. If clinical applications are considered, a thorough
characterization of several individual clones needs to be undertaken prior to use, making a
widespread application of this approach today unlikely. Very recent reports indicate that fi‐
broblasts can be directly differentiated into several types of neurons and even neuronal pro‐
genitor cells in a much faster and more efficient way than through iPSing [91]. It remains to
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be evaluated to which extent these cells recapitulate neurodegenerative disease phenotypes,
although a first report from fibroblast derived neurons from a familial Alzheimer’s patient
seem promising [92].
In summary, the technique of reprogramming holds great promises in terms of disease mod‐
eling and unraveling of underlying mechanisms of sporadic neurodegenerative diseases
such as ALS. Despite the current confusion due to the various methods used to generate the
lines, the observed clonal variations as well as the limited reflection of disease phenotypes,
the field has advanced with tremendous speed if one considers that the first report about
reprogramming of mouse fibroblasts was published only 6 years ago. With combined efforts
and improved methods, a better understanding and control of the reprogramming mecha‐
nisms can be achieved, thereby facilitating the interpretation and usage of the generated
cells.
6. Future trends in modeling ALS and discovering new therapies
The recent remarkable advancement in the cell biology field that adult fibroblasts can be re‐
programmed to virtually originate all cell types have created a unique opportunity to model
neurological disorders in vitro. iPS technology has already been applied to several neurode‐
generative conditions, from Alzheimer’s disease [93] to Down syndrome [94], as well schizo‐
phrenia [80], Rett syndrome [95] and ALS [14].
Although a large number of iPS cell lines from patients affected by various diseases have
been made commercially available, it is still not clear how robustly these recapitulate the
characteristics specific of each disease. Although the promises of iPS technology are to lead
to high-throughput screenings to find new efficacious therapeutic targets, they are subject to
some main limitations that have already been addressed in other sections of this book chap‐
ter. It is, therefore, of paramount importance that the properties of the differentiated cells
are well characterized and it is verified that they are representative of the disease they are
modeling.
However, some promising results have been obtained from a very recent study suggesting
that iPS-derived motor neurons originated from patients carrying TDP-43 mutations display
abnormalities typical of TDP-43 proteinopathy. These cells display elevated levels of soluble
and detergent-resistant TDP-43 protein, decreased survival, and increased vulnerability to
inhibition of phosphatidylinositol 3-kinase (PI3K) pathway [78] as well as shorter neurites
and TDP-43 cytoplasmic aggregates [82]. These parameters can be used as readout for high-
throughput drug screenings as well as short hairpin RNA (shRNA) library screenings. In‐
deed, Egawa and colleagues performed microarray analysis on iPS-derived motor neurons
transduced with lentivirus expressing green fluorescent protein (GFP) under the control of
the HB9 promoter. Based on the results obtained from gene expression analysis, the authors
tested 4 drugs known to modulate transcription through histone modification and RNA
splicing. Using the high content imaging analyzer InCell 6000, Egawa and colleagues found
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that anacardic acid had protective effects against arsenite-induced motor neuron death and
was able to decrease TDP-43 cytoplasmic aggregates as well as increase neurite length [82].
A different approach was taken in 2011 by Haidet-Phillips and colleagues [15], producing
cells from patients without the use of viral vectors or induction of major epigenetic modi‐
fications.  In  this  study,  astrocytes  were  derived from NPCs isolated  from ALS patients
and it was observed that, regardless of their familial or sporadic origin, these cells were
toxic to wild type murine motor neurons expressing GFP under HB9 promoter [15]. The
authors  found that  SOD1 knockout via  shRNA could rescue motor neurons at  different
extents  depending  on  whether  these  were  co-cultured  on  astrocytes  from  familial  or
sporadic  cases.  This  study overcomes some of  the  major  issues  related to  iPS  cells  and
sets the premises for drug and shRNA screening to target pathways and single genes in‐
volved in astrocyte toxicity.
Concluding, it is clear that in the past five years the ALS field has seen a major change of
scenario, where more tools are available to study more forms of FALS as well as the striking
majority of SALS. As the recent genetic discoveries have highlighted the importance of pre‐
viously unexplored pathways, i.e. RNA metabolism, also common targets linking sporadic
and familial ALS have been identified, i.e. TDP-43 and SOD-1. Moreover, the advances in
highthroughput screening technology with the advent of new gene profiling techniques, i.e.
deep-sequencing, and high content imaging systems are bound to determine the beginning
of a new era for ALS research.
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